TTK and ovarian carcinoma: NSC777201 demonstrated antiproliferative and dose-dependent anticancer activity against the NCI’s ovarian cancer cell lines, and its further evaluation towards TTK, NEK2, and CDK1 inhibition was carried out with in silico docking in a receptor-ligand interaction study.